logo-loader

Berkeley Energia announces potential cost savings at Salamanca mine

Published: 02:32 09 Jul 2018 EDT

1531118403_uranium-mining_134109206
Berkeley Energia said the proposed modifications remain consistent with the future expansion of production from Zona 7 and Alameda

Berkeley Energia LTD (LON:BKY) has announced that the capital cost review initiated by the company has identified a number of opportunities to reduce the initial capital expenditure  at the Salamanca mine, required to bring it into production.

The company said potential saving of up to €9mln arise from optimisation of plant capacities, outsourcing of peripheral infrastructure and reducing initial throughput for production from the Retortillo deposit.

READ: Berkeley Energia thanks government of Castilla y León for continued support

The initiatives proposed will be taken forward to detailed engineering in parallel with the commencement of planned on-site construction activity, including site preparation, bulk earthworks and initial civil construction works.

Berkeley Energia said the proposed modifications remain consistent with the future expansion of production from Zona 7 and Alameda.

Paul Atherley, managing director and CEO, said:"The review has identified potential up-front cost savings at the Salamanca mine which capitalises on the well-established EU infrastructure.”

He added: “There is strong local support for our mine from nearby residents, over 25% of whom have applied for jobs with us, and from Salamanca's business community, who turned out in force with over 200 people attending our recent update evening at the historic Colegio Arzobispo Fonseca.”

“Looking forward the €250 million investment by London Main Board listed Berkeley will be an important post Brexit bilateral trade deal,” Atherley said.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 48 minutes ago